Kivo reports a rise in FDA warning letters to drug firms due to documentation failures, with 94% citing recordkeeping issues.
This item is available in full to subscribers.
To continue reading, you will need to either log in to your subscriber account, below, or purchase a new subscription.
Please log in to continue |